Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid antibodies.

S R Levine1, K M Welch

  • 1Department of Neurology, Henry Ford Hospital, Detroit, MI 48202.

Annals of Neurology
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Antiphospholipid antibodies, like lupus anticoagulants and anticardiolipin antibodies, are linked to a higher risk of thrombosis and ischemic cerebrovascular disease. Further research is needed to understand their role in brain disease and guide treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue plasminogen activator for acute ischemic stroke in patients with unruptured cerebral aneurysms.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2013
Same author

Sumatriptan and migraine-induced stroke: the news is not all bad!

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

NSA and the Japan Stroke Society.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Moyamoya syndrome associated with Sneddon's syndrome and antiphospholipid-protein antibodies.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Preface.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Acute stroke care early in the 21(st) century.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same journal

AQP4 and MOG Characterize the Autoantibody Landscape of Checkpoint Blockade-Induced Optic Neuritis.

Annals of neurology·2026
Same journal

Five Issues of Artificial Intelligence in Science: Sailing the Ship of Theseus.

Annals of neurology·2026
Same journal

Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

Annals of neurology·2026
Same journal

Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

Annals of neurology·2026
Same journal

Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

Annals of neurology·2026
Same journal

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Immunology
  • Cardiology

Background:

  • Antiphospholipid antibodies (aPL), including lupus anticoagulants and anticardiolipin antibodies, are increasingly recognized as indicators of thrombosis risk.
  • Ischemic cerebrovascular disease is a significant clinical manifestation associated with aPL.
  • The pathogenetic role of aPL in neurological conditions remains an area of active investigation.

Purpose of the Study:

  • To review the evidence supporting and refuting the role of antiphospholipid antibodies in the pathogenesis of ischemic brain disease.
  • To comment on the current laboratory methods used for detecting antiphospholipid antibodies.
  • To outline future research directions for aPL in neurological diseases.

Main Methods:

  • Literature review of existing studies on antiphospholipid antibodies and ischemic cerebrovascular disease.

Related Experiment Videos

  • Analysis of evidence for and against the pathogenic role of aPL.
  • Evaluation of current diagnostic laboratory assays for aPL detection.

    • Main Results:

    • Established association between antiphospholipid antibodies and increased risk of thrombosis, particularly ischemic cerebrovascular events.
    • Mixed evidence regarding the direct pathogenetic role of aPL in ischemic brain disease.
    • Overview of available laboratory techniques for aPL detection, with implicit commentary on their utility.

    Conclusions:

    • Antiphospholipid antibodies are significant risk markers for thrombosis, including stroke.
    • Further research is crucial to elucidate the pathogenicity of aPL in neurological disorders.
    • Future studies should focus on high-risk patient identification, prospective natural history studies, and treatment protocols for neurological manifestations of antiphospholipid syndrome.